CURRENT TOPICS IN RADIATION AND CANCER BIOLOGY (FRRB:6008)
SCHEDULE OF PRESENTATIONS
Spring 2025 (Director: Dr. Douglas Spitz)
11:30 AM - 12:30 PM, Every Other Monday, Location Variable

Presentations for Spring 2025:

January 20, 2025

Office Closed, MLK Jr. Day

February 3, 2025

Presenter: Prabhat Goswami

Paper: Di Bona M, Chen Y, Agustinus AS, Mazzagatti A, Duran MA, Deyell M, Bronder D, Hickling J, Hong C, Scipioni L, Tedeschi G, Martin S, Li J, Ruzgaitė A, Riaz N, Shah P, D'Souza EK, Brodtman DZ, Sidoli S, Diplas B, Jalan M, Lee NY, Ordureau A, Izar B, Laughney AM, Powell S, Gratton E, Santaguida S, Maciejowski J, Ly P, Jeitner TM, Bakhoum SF. Micronuclear collapse from oxidative damage. Science. 2024 Aug 30;385(6712):eadj8691. doi: 10.1126/science.adj8691. Epub 2024 Aug 30. PMID: 39208110; PMCID: PMC11610459.

February 17, 2025

Presenter:  Douglas Spitz

Paper: Liu Y, Liu S, Tomar A, Yen FS, Unlu G, Ropek N, Weber RA, Wang Y, Khan A, Gad M, Peng J, Terzi E, Alwaseem H, Pagano AE, Heissel S, Molina H, Allwein B, Kenny TC, Possemato RL, Zhao L, Hite RK, Vinogradova EV, Mansy SS, Birsoy K. Autoregulatory control of mitochondrial glutathione homeostasis. Science. 2023 Nov 17;382(6672):820-828. doi: 10.1126/science.adf4154. Epub 2023 Nov 2. PMID: 37917749; PMCID: PMC11170550.

March 3, 2025

Presenter: Michael Petronek

Paper: Wang H, Shi H, Rajan M, Canarie ER, Hong S, Simoneschi D, Pagano M, Bush MF, Stoll S, Leibold EA, Zheng N. FBXL5 Regulates IRP2 Stability in Iron Homeostasis via an Oxygen-Responsive [2Fe2S] Cluster. Mol Cell. 2020 Apr 2;78(1):31-41.e5. doi: 10.1016/j.molcel.2020.02.011. Epub 2020 Mar 2. PMID: 32126207; PMCID: PMC7159994.

March 17, 2025
Spring Break

March 31, 2025 (location: B111 ML)

Presenter: Michael Schrodt

Paper: DeAngelo SL, Zhao L, Dziechciarz S, Shin M, Solanki S, Balia A, El-Derany MO, Castillo C, Qin Y, Das NK, Bell HN, Paulo JA, Zhang Y, Rossiter NJ, McCulla EC, He J, Talukder I, Ng BW, Schafer ZT, Neamati N, Mancias JD, Koutmos M, Shah YM. Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer. bioRxiv [Preprint]. 2024 Aug 27:2024.03.29.587381. doi: 10.1101/2024.03.29.587381. PMID: 38617233; PMCID: PMC11014488.

April 14, 2025 (location: 1180 ML)

Presenter: Ellen Voigt

Paper: Kumar S, Ziegler Y, Plotner BN, Flatt KM, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS. Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death. Breast Cancer Res Treat. 2024 Nov;208(2):307-320. doi: 10.1007/s10549-024-07420-9. Epub 2024 Jul 9. PMID: 38980505; PMCID: PMC11455716.

April 28, 2025 (location: 1180 ML)

Presenter: Akshaya Warrier

Paper: Liu Q, Hu J, Li X, Gao H, Kong D, Jin M. Glutamine transporter inhibitor enhances the sensitivity of NSCLC to trametinib through GSDME-dependent pyroptosis. Biochem Pharmacol. 2025 Mar;233:116796. doi: 10.1016/j.bcp.2025.116796. Epub 2025 Feb 7. PMID: 39923858.